Gilead Sciences warns of inadequate anti-HIV drug regimen
BY Advocate.com Editors
October 16 2003 12:00 AM ET
In a letter sent Tuesday to health care providers around the country, drugmaker Gilead Sciences warns that an anti-HIV drug regimen that contains Videx EC (ddI) and Epivir (3TC), both manufactured by GlaxoSmithKline, and Gilead's medication Viread can result in poor virologic control and the development of drug-resistant virus. The letter says a study of the triple-drug regimen was halted because of a high rate of early virologic failure and the emergence of genetic mutations conveying resistance to nucleoside reverse transcriptase inhibitors. Based on the study results, Gilead does not recommend the use of Viread with ddI and 3TC for either patients newly starting antiretroviral therapy or for treatment-experienced patients. Patients currently taking that regimen should be considered for a change to a different drug cocktail, the company suggests.
The Gilead letter was prompted by clinical trial data showing a 91% virologic failure rate as observed by low reductions in HIV viral loads after 12 weeks of treatment. About 95% of trial participants had virus that developed a particular genetic mutation conveying drug resistance during the clinical trial, while the virus in about half the study volunteers developed two such genetic mutations. Other studies have shown similar results when evaluating triple-NRTI anti-HIV regimens. Studies of the Glaxo combination drug Trizivir, which contains AZT, 3TC, and Ziagen, and of a Ziagen-ddI-d4T combination also showed poor virologic response to the medications.
- Even the Rehearsal Footage From Madonna's Rebel Heart Tour Is Spellbinding
- The Top 175 Essential Films of All Time for LGBT Viewers
- #TBT: They Died in the Closet
- Hundreds Attend Satanic Statue Unveiling in Detroit Despite Terrorist Threats
- Op-ed: How We Can Address Homophobia at the Doctor's Office
- These Are the U.S. Trans Women Killed in 2015